Findings from the LIO-1 Trial in advanced metastatic tumors
In a recent video from OncLive, Erika P. Hamilton, MD, highlights the initial findings from the ongoing phase 1b/2 LIO-trial in advanced metastatic tumors.
In the phase 1b portion of the study, researchers investigated the recommended dose of lucitanib in combination with nivolumab in patients with advanced solid tumors. Complete and partial responses were demonstrated in 17 patients who received the combination, according to Hamilton. Stable disease was also reported in 10 patients.
These data were seen across several tumor types, including those that do not typically respond to immunotherapy. The combination is now being evaluated further in phase 2 of the trial.
For more information, watch the video and visit OncLive.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
